# PROJECT 3: Quality of T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus Vaccination > **NIH NIH P01** · UNIVERSITY OF CALIFORNIA BERKELEY · 2023 · $274,350 ## Abstract PROJECT 3: Quality of T-Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus Vaccination (La Jolla Institute for Allergy and Immunology) SUMMARY The overall theme of the P01 is to study and reveal the role of adaptive immunity in the context of DENV infection and vaccination, in terms of shaping clinical and virological endpoints and outcomes. In Project 3, we will specifically address the central issue of the relation between quality of T cell responses and clinical outcomes as well as antibody quality and durability. Beyond accurately measuring magnitude and number of DENV-specific T cells, we will thoroughly define the quality of T cell responses. First, we will study the antigens targeted by DENV-specific T cells; for example, are envelope (E)-specific T cell responses more effective for helping B cells? Are non-structural (NS) protein-derived responses better for providing help for killing infected targets by CD8 T cells? Second, we will examine another important component of response quality, namely its cross-reactivity among DENV serotypes, or with the vectors used in vaccination. This issue is of relevance in the context of the suboptimal performance of the first licensed DENV vaccine (Dengvaxia®), which utilizes DENV-derived E proteins expressed in a yellow fever virus backbone, which lacks DENV NS proteins. Third, we will determine the CD4 and CD8 subsets elicited by infection and vaccination, in terms of which memory subsets drive responses, what their specific transcriptomic profiles are, to what degree effector responses are multi-specific, and how narrow or diverse the T cell receptor (TCR) repertoire of DENV-specific T cell is. This comprehensive analysis will allow to ask the questions: What drives quality? And how does quality influence outcomes? Our hypothesis is that the quality of T cell responses influences the clinical outcomes of infection and vaccination, either by direct effector functions of DENV-specific T cells, or indirectly, through modulation of the quantity and quality of B cell responses. This hypothesis will be tested by characterizing the quantity and quality of memory T cell responses prior to either symptomatic (DF or severe dengue disease) or inapparent DENV infection in samples distributed by Core C from the Pediatric Dengue Cohort Study in Nicaragua (Aim 1). We will also investigate the role of T cell help in relation to antibody quality and durability (Project 1). Further, we will utilize samples collected 12-18 month after Dengvaxia® vaccination in the Philippine cohort (Core C), and specifically focus on differences observed in DENV-seronegative versus -seropositive vaccinees prior to vaccination (Aim 2). In parallel, we will analyze samples from vaccinees who experience breakthrough DENV infections after vaccination. The variables considered to define “quality” will include: magnitude of antigen- specific T cell response, definition of the dominant antigenic targets, cross-r... ## Key facts - **NIH application ID:** 10690790 - **Project number:** 5P01AI106695-09 - **Recipient organization:** UNIVERSITY OF CALIFORNIA BERKELEY - **Principal Investigator:** Daniela Weiskopf - **Activity code:** P01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2023 - **Award amount:** $274,350 - **Award type:** 5 - **Project period:** 2015-07-29 → 2025-07-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10690790 ## Citation > US National Institutes of Health, RePORTER application 10690790, PROJECT 3: Quality of T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus Vaccination (5P01AI106695-09). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10690790. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*